Summit Therapeutics Inc. - 8-K Filing

Summit Therapeutics reports Q2 financial results and clinical updates on ivonescimab including updated OS data for HARMONi trial (Items: 2.02 as if fully set forth herein, 7.01 as if fully set forth herein)

SEC EDGAR ·

Tickers: $SMMT

Read the full article at SEC EDGAR

More Regulatory news